Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07446998) titled 'Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Veru Inc.
Condition:
Obesity & Overweight
Mobility Disability
HOMA-IR
Intervention:
Drug: Enobosarm
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 2026
Target Sample Size: 200
Countries of Re...